A PATIENT RECEIVING IMMUNOSUPPRESSIVE THERAPY IN CORONAVIRUS PANDEMIC (SARS-COV-2)
Abstract
Coronavirus 2019 (COVID-19) is a severe acute respiratory infection (TORI) caused by the new coronavirus SARS-CoV-2. The SARS-CoV-2 virus is a single-stranded stranded RNA virus with nucleocapside. Sequencing of its complete genome has shown that it is closely related to SARS-CoV, with which it shares about 79 % of its genome. The article describes the pathogenesis of COVID-19 and potential approaches to treating patients as well as approaches to patient management after transplantation with COVID-19.
About the Authors
B. I. Yaremin
State Budgetary Healthcare Institution ‘N.V. Sklifosovsky Research Institute of Emergency Medicine’
Russian Federation
Samara
Russian Federation
Samara
P. Kh. Nazarov
Scientific Center for Organ Transplantation
Tajikistan
Tajikistan
E. V. Parabina
Federal State Budgetary Institution of Higher Education ‘Samara State Medical University’, Ministry of Health of the Russian Federation
Russian Federation
Samara
Russian Federation
Samara
D. Yu. Konstantinov
Federal State Budgetary Institution of Higher Education ‘Samara State Medical University’, Ministry of Health of the Russian Federation
Russian Federation
Samara
Russian Federation
Samara
U. V. Maslikova
Federal State Budgetary Institution ‘National Medical Research Center of Hematology’, Ministry of Health of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
M. S. Novruzbekov
State Budgetary Healthcare Institution ‘N.V. Sklifosovsky Research Institute of Emergency Medicine’
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Lorenzo D'Antiga Coronaviruses and immunosuppressed patients. The facts during the third epidemic // Liver Transplantation, Volume 26, Issue 4, April 2020 20 March 2020, https://doi.org/10.1002/lt.25756.
2. Memoli MJ, Athota R, Reed S, Czajkowski L, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214-24.
3. Mandl JN, Ahmed R, Barreiro LB, Daszak P, et al. Reservoir host immune responses to emerging zoonotic viruses. Cell 2015;160:20–35.
4. Stockman LJ, Massoudi MS, Helfand R, Erdman D, et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J. 2007;26:68-74.
5. Hui DS, Azhar EI, Kim YJ, Memish ZA, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217-e227.
6. Liang W, Guan W, Chen R, Wang W, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-337.
7. Chui AK, Rao AR, Chan HL, Hui AY. Impact of severe acute respiratory syndrome on liver transplantation service. Transplant Proc 2004;36:2302-3.
8. Michaels MG, La Hoz RM, Danziger-Isakov L, Blumberg EA, Kumar D, Green M, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020 Feb 24. PMID: 32090448 http://doi.org/10.1111/ajt.15832.
9. Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003;3:977-81.
10. Lorenzo D'Antiga Coronaviruses and immunosuppressed patients. The facts during the third epidemic// Liver Transplantation, Volume 26, Issue 4, April 2020 20 March 2020, https://doi.org/10.1002/lt.25756.
11. Spanish recommendations to manage organ donation and transplantation related to the infection associated with new coronavirus (SARS-CoV-2), producer of COVID-19. Biovigilance alert reference BV-ES-20200122-5. Last update 13 march 2020.
12. P. Sarzi-Puttini1, V. Giorgi2, S. Sirotti3 et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clinical and Experimental Rheumatology 2020.
13. Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112–117. doi:10.1016/j.virusres.2012.02.002.
14. Carbajo-Lozoya J, Ma-Lauer Y, Malešević M, et al. Human coronavirus NL63 replication is cyclophilin Adependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 2014;184:44–53. doi:10.1016/j.virusres.2014.02.010.
15. Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, Sasaki T. Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res. 2012;43(1):41. Published 2012 Apr 30. doi:10.1186/1297-9716-43-41.
16. Andrea, G., Daniele, D., Barbara, A., Davide, M., Laura, A., Paolo, R., Alessandra, B. and Giorgio, R. (2020), Coronavirus Disease 2019 and Transplantation: a view from the inside. Am J Transplant. Accepted Author Manuscript. doi:10.1111/ajt.15853.
17. Huang, J., Lin, H., Wu, Y., Fang, Y., Kumar, R., Chen, G. and Lin, S. (2020), COVID-19 in post-transplantation patients- report of two cases. Am J Transplant. Accepted Author Manuscript. doi:10.1111/ajt.15896.
18. Teicher E, Vincent I, Bonhomme-Faivre L, et al. "Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study." Clin Pharmacokinet 46 (2007): 941-52.
19. Babenko N.N., Goryajnov V.A., Kaabak M.M., Nikoda V.V., Lishova E.A. Ispol'zovanie belatasepta pri pere-sadke pochki. Transplantologiya. 2018;10(3):222-231. https://doi.org/10.23873/2074-0506-2018-10-3-222-231.
Review
For citations:
Yaremin B.I., Nazarov P.Kh., Parabina E.V., Konstantinov D.Yu., Maslikova U.V., Novruzbekov M.S. A PATIENT RECEIVING IMMUNOSUPPRESSIVE THERAPY IN CORONAVIRUS PANDEMIC (SARS-COV-2). Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2020;(2):76-84. (In Russ.)
Views:
396
Email this article 